how will you raise new capital without the sale of new shares - a lot of new shares? new shares and R/S plus new debt from the medical device or still more shares to pay for it? altogether terrible more shares. there remains nearly no value for the old shares. further: how big is the discrepancy between the asset values of EPGL and the debt? or are there hidden reserves in EPGL? it follows we need an audited actual balance-sheet. don´t forget: the current shareholders have the votes. I will vote "yes" only, if I see a massive debt reduction (in the proposed restructuring) or a kind of "debt release and exchange agreement" as described earlier (#19377). we must prevent that the current shareholders are wiped out - in the sense iblong2 has described it -, only to pay the debt with PWC.
Market Data 
Markets 
AI
